Anti-CD47 Antibody-Drug Conjugate for TNBC Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Triple-negative breast cancers (TNBCs) develop drug resistance and metastasis due to ATP-binding cassette transporters, cancer stem cells, hypoxia, apoptosis dysregulation, and signaling pathway activation, leading to adverse effects, early relapse, and poor survival rates with standard chemotherapies.
Innovation Solution
Development of an antibody that selectively binds to CD47 on tumor cells, specifically a monoclonal antibody with defined CDR sequences, which can be humanized or chimeric, and conjugated with cytotoxins like auristatin or calicheamicin to form an antibody-drug conjugate (ADC) for targeted therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard cytotoxic chemotherapies are used to treat TNBC, then initial tumor response is achieved, but drug resistance develops and metastasis occurs
Solution Approach 1:
The patent segments the treatment approach by using combination therapy with multiple antibodies targeting different pathways (CD47, PD-L1, HER2) simultaneously, rather than relying on a single cytotoxic chemotherapy agent. This multi-targeted segmentation prevents the development of resistance to any single agent while maintaining initial efficacy.
Solution Approach 2:
The patent employs a composite therapeutic approach by combining multiple monoclonal antibodies (anti-CD47, anti-PD-L1, anti-HER2) into a single treatment regimen. This composite strategy addresses multiple tumor mechanisms simultaneously, thereby extending the duration of therapeutic response and preventing metastasis that occurs with monotherapy.
2Reliability
If standard chemotherapies are administered repeatedly, then tumor control is attempted, but adverse effects accumulate and survival rate remains poor
Solution Approach 1:
The patent introduces targeted antibody mediators that specifically bind to tumor cell surface markers (CD47, PD-L1, HER2) rather than using non-specific cytotoxic chemotherapies. This intermediary approach delivers therapeutic effects directly to tumor cells while sparing normal tissues, thereby maintaining treatment reliability while significantly reducing cumulative adverse effects.
Solution Approach 2:
The patent changes the fundamental parameter of treatment specificity by transitioning from non-specific chemotherapy to highly specific monoclonal antibody therapy. This parameter change allows repeated administrations to maintain tumor control while minimizing adverse effects, as the antibodies selectively target tumor cells expressing specific markers rather than affecting all rapidly dividing cells.
3Reliability
If high-dose chemotherapy is used to overcome drug resistance, then tumor cell kill is increased, but toxicity to normal cells increases
Solution Approach 1:
The patent applies local quality by designing antibodies that specifically recognize and bind to tumor cell surface markers (CD47, PD-L1, HER2) that are locally expressed on cancer cells but absent or minimally expressed on normal cells. This localized targeting ensures high tumor cell kill efficacy while minimizing toxicity to normal cells, as the therapeutic effect is confined to cells expressing the target markers.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The anti-CD47 ADC demonstrates effective in vitro and in vivo targeting and cytotoxicity against TNBC cells, reducing tumor volume and weight with minimal immune toxicity, offering a promising treatment for drug-resistant TNBCs.
Implementation Method 1
an antibody that selectively binds CD47 on tumor cells
Implementation Method 2
conjugated with cytotoxins like auristatin or calicheamicin to form an antibody-drug conjugate (ADC) for targeted therapy
Data Source
AI summary
Disclosed is an antibody that selectively binds CD47 on tumor cells. Also disclosed is a method for treating cancer in a subject, comprising administering to the subject an effective amount of the antibody disclosed.